Clinical trials: Muscle-Invasive Bladder Cancer (MIBC), open to volunteers
Muscle-Invasive Bladder Carcinoma
Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer
Evaluate the impact of 18F-FDG-PET-CT on the staging of patients with muscle invasive bladder cancer. Based on the results of 2 18F-FDG-PET-CT's patients are stratified in non-metastatic, oligometastatic and polymetastatic…
- Trial name
- EFFORT-MIBC (NCT04724928)
- Testing
- Metastasis directed therapy (MDT), Immunotherapy, Standard of care
- Where
- Belgium
- Volunteers
- 156 people
- Sponsor
- University Hospital, Ghent
Muscle-Invasive Bladder Cancer (MIBC), Urinary Bladder Cancer
Multi-Omics-Based Phase Ⅱ Trial of Trastuzumab Rezetecan Plus Camrelizumab for Perioperative Therapy in HER2-Positive Muscle-Invasive Urothelial Carcinoma
For patients with HER2-expressing muscle-invasive bladder cancer (MIBC), current neoadjuvant therapies dominated by platinum-based chemotherapy remain unsatisfactory with respect to improved clinical efficacy, pathological…
- Trial name
- NCT07639983
- Testing
- Trastuzumab Rezetecan plus Camrelizumab
- Volunteers
- 44 people
- Sponsor
- Sheng Tai
Muscle-Invasive Bladder Carcinoma
Predicting Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer
Bladder cancer (BC) is the 10th most commonly diagnosed cancer worldwide and the second most common cancer among Egyptian males.
- Trial name
- NCT06325423
- Testing
- neoadjuvant chemotherapy
- Volunteers
- 50 people
- Sponsor
- Assiut University
Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC)
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
This is a multicenter, non-interventional, prospective and retrospective observational patient registry study of adults with muscle-invasive bladder cancer receiving perioperative systemic therapy as part of routine clinical…
- Trial name
- GUARDIANS (NCT07855926)
- Testing
- Perioperative Systemic Therapy Registry
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- LMU Klinikum
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer, Urothelial Carcinoma (UC)
Comparison of CT and MR (VI-RADS) Imaging for Local Bladder Cancer Staging
This prospective diagnostic accuracy study compares computed tomography (CT) and multiparametric magnetic resonance imaging (MRI) using the Vesical Imaging-Reporting and Data System (VI-RADS) for local staging of newly diagnosed…
- Conditions
- Bladder Cancer, Urothelial Carcinoma (UC), Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
- Trial name
- NCT07602010
- Where
- Norway
- Volunteers
- 150 people
- Sponsor
- Oslo University Hospital
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
RC48 Combined With Toripalimab as Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
A single-arm, prospective, exploratory clinical trial to explore the pathological complete response (pCR) rate of immune checkpoint inhibitors combined with antibody conjugate drugs as the perioperative treatment of…
- Trial name
- NCT06341400
- Testing
- DisitamabVedotinForIicction Toripalimab
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Zhujiang Hospital
Urinary Bladder Neoplasms
A Study of Radical Cystectomy in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) and Muscle Invasive Bladder Cancer (MIBC) in Korea
The purpose of this study is to assess participant's overall well-being and the extent to which medical services are used by participants with non-muscle invasive bladder cancer (NMIBC) and muscle invasive bladder cancer (MIBC)…
- Trial name
- BC RC DB (NCT07735793)
- Volunteers
- 1 people
- Sponsor
- Janssen Korea, Ltd., Korea
Muscle-Invasive Bladder Cancer (MIBC)
Response-Guided Bladder Preservation With Trastuzumab Rezetecan, Adebrelimab, and Concurrent Bladder Radiotherapy in HER2-Expressing Muscle-Invasive Bladder Cancer
This prospective, multicenter, open-label phase II study will evaluate a response-guided bladder-preservation strategy in patients with HER2-expressing muscle-invasive bladder cancer.
- Trial name
- RG-BP-MIBC (NCT07865611)
- Testing
- Trastuzumab Rezetecan, Adebrelimab, Concurrent Bladder Radiotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Tongji Hospital
Muscle Invasive Bladder Cancer (MIBC)
Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC
The goal of this clinical trial is to learn if oral probiotics (Clostridium butyricum) work to improve the efficacy of targeted therapy plus immunotherapy in bladder preservation setting for cisplatin-ineligible T2-3N0M0 bladder…
- Trial name
- NCT07474064
- Testing
- Probiotic, Disitamab Vedotin, Toripalimab
- Where
- China
- Volunteers
- 146 people
- Sponsor
- chenxu
Muscle-Invasive Bladder Cancer (MIBC)
A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-Invasive
This is a Phase 4, Single Arm Study To Assess The Safety and tolerability of Perioperative Durvalumab in Combination with Neoadjuvant Gemcitabine Plus Cisplatin Treatment Followed by radical cystectomy and Durvalumab alone as…
- Trial name
- SERENE (NCT07876817)
- Testing
- Durvalumab, Gemcitabine, Cisplatin
- Volunteers
- 50 people
- Sponsor
- AstraZeneca
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University
Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC)
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
Radical cystectomy is the standard of care for muscle invasive bladder cancer, however despite advances, it is still associated with high morbidity.
- Conditions
- Bladder Cancer, Muscle Invasive Bladder Cancer (MIBC), Muscle Invasive Bladder Cancer Urothelial Carcinoma, Cystectomy
- Trial name
- NCT07225205
- Testing
- Intravenous fluids, ERAS
- Where
- 2 sites in United States
- Volunteers
- 130 people
- Sponsor
- Johns Hopkins University
NMIBC, MIBC
Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)
This study aims to better understand how treatment choices impact outcomes for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC), as well as the factors that influence treatment decisions made…
- Conditions
- NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
- Trial name
- BLAST (NCT07893509)
- Testing
- This is a non-interventional, observational, prospective study.
- Where
- United States
- Volunteers
- 1,400 people
- Sponsor
- Bladder Cancer Advocacy Network
Muscle Invasive Bladder Cancer (MIBC)
Neoadjuvant Zanidatamab + Tislelizumab + Chemotherapy for Selective Bladder Preservation in HER2-Positive MIBC
This is a multicenter, open-label, prospective, single-arm, phase II study designed to evaluate the efficacy and safety of neoadjuvant zanidatamab combined with tislelizumab and chemotherapy, followed by selective bladder…
- Trial name
- HARBOR (NCT07296705)
- Testing
- Zanidatamab, Tislelizumab, Cisplatin
- Where
- 12 sites in China
- Volunteers
- 25 people
- Sponsor
- Fujian Medical University Union Hospital
Muscle-Invasive Bladder Cancer (MIBC)
EV + Toripalimab vs GC as Neoadjuvant Therapy in Locally Advanced/High-Risk MIBC
The purpose of this Phase II, open-label, multicenter, randomized controlled study is to evaluate the efficacy and safety of Enfortumab Vedotin in combination with Toripalimab compared to Gemcitabine plus Cisplatin.
- Trial name
- NCT07647289
- Testing
- enfortumab vedotin (EV), Toripalimab, Gemcitabine (Chemotherapy)
- Where
- China
- Volunteers
- 58 people
- Sponsor
- Peking University Third Hospital
Muscle Invasive Bladder Cancer (MIBC)
RESTORE-BLADDER (REgistry on STrategies for Organ pREservation in Muscle-invasive BLADDER Cancer)
Removal of the urinary bladder (radical cystectomy) is a major surgical procedure that can have a permanent impact on a patient's quality of life.
- Trial name
- NCT07744958
- Testing
- None. Registry.
- Volunteers
- 100 people
- Sponsor
- Heinrich-Heine University, Duesseldorf
Bladder Cancer, Muscle-invasive Bladder Cancer
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
This is a single-arm, open-label, Phase Ib/II clinical trial designed to evaluate the efficacy and safety of Disitamab Vedotin combined with Ivonescimab in the perioperative treatment of cisplatin-ineligible patients with…
- Trial name
- DIVON (NCT06957561)
- Testing
- Disitamab Vedotin Injection, Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）, Radical Cystectomy with Pelvic Lymph Node Dissection
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sun Yat-sen University
Muscle-invasive Bladder Cancer
Diagnostic Accuracy of 18F-FDG PET/CT in Muscle-invasive Bladder Cancer
MIBC-PET is a prospective, monocentric, no-profit study with paired imaging comparison enrolling 60 patients with newly diagnosed, histologically confirmed high-grade MIBC.
- Trial name
- MIBC-PET (NCT07750470)
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- University Hospital of Ferrara
Muscle-Invasive Bladder Carcinoma, Tumor
Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology
This is a Phase II, single cohort study designed to evaluate outcomes in patients with muscle invasive bladder cancer (MIBC) with variant histology who receive neoadjuvant chemotherapy (NAC) with or without immunotherapy (IO)…
- Trial name
- NCT06417190
- Testing
- Trimodal therapy (TMT) within 45 days of neoadjuvant chemotherapy (NAC)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Leslie Ballas